| Authors: |
Vilar M; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America; Neurodegeneration Unit, Chronic Disease Program, Spanish Institute of Health Carlos III, Madrid, Spain., Sung TC; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America., Chen Z; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America., García-Carpio I; Neurodegeneration Unit, Chronic Disease Program, Spanish Institute of Health Carlos III, Madrid, Spain., Fernandez EM; Neurodegeneration Unit, Chronic Disease Program, Spanish Institute of Health Carlos III, Madrid, Spain., Xu J; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America., Riek R; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America; Laboratory for Physical Chemistry, ETH Zürich, Zürich, Switzerland., Lee KF; Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, United States of America. |